N
145.00
3.16 (2.23%)
| 前收盘价格 | 141.84 |
| 收盘价格 | 142.97 |
| 成交量 | 1,983,725 |
| 平均成交量 (3个月) | 1,015,263 |
| 市值 | 14,457,325,568 |
| 市盈率 (P/E TTM) | 34.61 |
| 预期市盈率 (P/E Forward) | 19.84 |
| 价格/销量 (P/S) | 5.40 |
| 股市价格/股市净资产 (P/B) | 4.71 |
| 52周波幅 | |
| 利润日期 | 5 Feb 2026 |
| 营业毛利率 | 12.68% |
| 营业利益率 (TTM) | 4.14% |
| 稀释每股收益 (EPS TTM) | 2.95 |
| 季度收入增长率 (YOY) | 11.10% |
| 季度盈利增长率 (YOY) | -81.80% |
| 总债务/股东权益 (D/E MRQ) | 19.45% |
| 流动比率 (MRQ) | 3.13 |
| 营业现金流 (OCF TTM) | 529.90 M |
| 杠杆自由现金流 (LFCF TTM) | 235.48 M |
| 资产报酬率 (ROA TTM) | 8.75% |
| 股东权益报酬率 (ROE TTM) | 12.43% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Neurocrine Biosciences, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
1.5
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.50 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Mid Core |
| 内部持股比例 | 1.06% |
| 机构持股比例 | 98.86% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 203.00 (Citigroup, 40.00%) | 购买 |
| 中 | 180.00 (24.14%) | |
| 低 | 164.00 (Canaccord Genuity, 13.10%) | 购买 |
| 平均值 | 184.00 (26.90%) | |
| 总计 | 11 购买, 2 保留 | |
| 平均价格@调整类型 | 143.56 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 08 Jan 2026 | 175.00 (20.69%) | 保留 | 135.99 |
| 11 Nov 2025 | 173.00 (19.31%) | 购买 | 147.29 | |
| HC Wainwright & Co. | 17 Dec 2025 | 198.00 (36.55%) | 购买 | 141.70 |
| Mizuho | 12 Dec 2025 | 175.00 (20.69%) | 保留 | 152.80 |
| Stifel | 11 Dec 2025 | 188.00 (29.66%) | 购买 | 154.75 |
| 29 Oct 2025 | 183.00 (26.21%) | 购买 | 138.02 | |
| RBC Capital | 08 Dec 2025 | 180.00 (24.14%) | 购买 | 154.99 |
| 29 Oct 2025 | 160.00 (10.34%) | 购买 | 138.02 | |
| TD Cowen | 05 Dec 2025 | 200.00 (37.93%) | 购买 | 155.51 |
| JP Morgan | 03 Nov 2025 | 179.00 (23.45%) | 购买 | 141.96 |
| Truist Securities | 30 Oct 2025 | 172.00 (18.62%) | 购买 | 138.04 |
| Canaccord Genuity | 29 Oct 2025 | 164.00 (13.10%) | 购买 | 138.02 |
| Citigroup | 29 Oct 2025 | 203.00 (40.00%) | 购买 | 138.02 |
| 21 Oct 2025 | 175.00 (20.69%) | 购买 | 142.65 | |
| Needham | 29 Oct 2025 | 184.00 (26.90%) | 购买 | 138.02 |
| Piper Sandler | 29 Oct 2025 | 179.00 (23.45%) | 购买 | 138.02 |
| UBS | 09 Oct 2025 | 195.00 (34.48%) | 购买 | 138.47 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合